Compare HURN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | VCEL |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2004 | 1996 |
| Metric | HURN | VCEL |
|---|---|---|
| Price | $146.25 | $34.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $215.50 | $58.50 |
| AVG Volume (30 Days) | ★ 465.8K | 415.3K |
| Earning Date | 05-27-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 5.84 | 0.32 |
| Revenue | ★ $1,699,143,000.00 | $276,259,000.00 |
| Revenue This Year | $11.74 | $20.11 |
| Revenue Next Year | $10.71 | $19.40 |
| P/E Ratio | ★ $25.41 | $107.28 |
| Revenue Growth | 11.65 | ★ 16.45 |
| 52 Week Low | $116.12 | $29.24 |
| 52 Week High | $186.78 | $51.45 |
| Indicator | HURN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 41.22 |
| Support Level | $132.80 | $34.61 |
| Resistance Level | $151.95 | $38.48 |
| Average True Range (ATR) | 7.13 | 1.67 |
| MACD | 2.85 | -0.24 |
| Stochastic Oscillator | 88.83 | 26.20 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.